Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery
- 31 January 2009
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (1), 194-212
- https://doi.org/10.1016/j.clinthera.2009.01.001
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 yearsCurrent Medical Research and Opinion, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplastyThe Journal of Bone and Joint Surgery. British volume, 2006
- Oral Anticoagulants in DevelopmentDrugs, 2006
- Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter UncertaintyValue in Health, 2005
- Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement SurgeryPharmacoEconomics, 2004
- Risk Factors of Recurrent Venous Thromboembolism: The Role of Residual Vein ThrombosisPathophysiology of Haemostasis and Thrombosis, 2003
- Economic Burden of Long-Term Complications of Deep Vein Thrombosis after Total Hip Replacement Surgery in the United StatesValue in Health, 2003
- Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip SurgeryValue in Health, 2000
- Postphlebitic syndrome after hip arthroplasty: 43 patients followed at least 5 yearsActa Orthopaedica, 1994